Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Eli Lilly and Co (NYSE:LLY)

80.88
Delayed Data
As of 4:01pm ET
 +1.36 / +1.71%
Today’s Change
67.88
Today|||52-Week Range
88.48
-4.01%
Year-to-Date
Eli Lilly (LLY) Upgraded at Goldman, Jim Cramer Weighs In
1:55pm / TheStreet.com - Paid Partner Content
Biosimilars in Limelight on FDA Approval of Amgen Drug
9:04am / Zacks.com - Paid Partner Content
Eli Lilly rises on Goldman recommendation
12:28pm / FT.com - Paid Partner Content
Eli Lilly (LLY) Stock Higher, Upgraded at Goldman
8:47am / TheStreet.com - Paid Partner Content
Eli Lilly Stock Upgraded: What You Need to Know
12:10pm / MotleyFool.com - Paid Partner Content
Analysts' Actions -- AutoZone, Eli Lilly, J.M. Smucker, Toll Brothers and More
8:11am / TheStreet.com - Paid Partner Content
Pfizer (PFE) to Stay Together as a Single Company After All
11:22am / Zacks.com - Paid Partner Content
Amgen's Biosimilar of Abbvie's Humira Gets FDA Approval
Sep 26 / Zacks.com - Paid Partner Content
Array (ARRY) Hits 52-Week High on Positive Phase III Data
10:19am / Zacks.com - Paid Partner Content
New Setback for Sanofi's Lantus Increases Need for M&A
Sep 22 / TheStreet.com - Paid Partner Content

Today’s Trading

Previous close79.52
Today’s open80.62
Day’s range79.61 - 80.93
Volume6,888,929
Average volume (3 months)3,815,365
Market cap$87.8B
Dividend yield2.52%
Data as of 4:01pm ET, 09/27/2016

Growth & Valuation

Earnings growth (last year)+1.35%
Earnings growth (this year)+4.58%
Earnings growth (next 5 years)+15.00%
Revenue growth (last year)+1.75%
P/E ratio34.9
Price/Sales4.50
Price/Book6.03

Competitors

 Today’s
change
Today’s
% change
NVONovo Nordisk-0.58-1.31%
AZNAstraZeneca+0.06+0.18%
BMYBristol-Myers Squibb+0.26+0.47%
CELGCelgene+1.09+1.03%
Data as of 4:02pm ET, 09/27/2016

Financials

Next reporting dateOctober 25, 2016
EPS forecast (this quarter)$0.96
Annual revenue (last year)$20.0B
Annual profit (last year)$2.4B
Net profit margin12.07%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
Chairman, President &
Chief Executive Officer
John C. Lechleiter
Chief Financial Officer &
EVP-Global Services
Derica W. Rice
Corporate headquarters
Indianapolis, Indiana

Forecasts

Search for Jobs